Why is IMMX down?
Down 3% on Nov 13, and still 14% under its Nov 12 close.
- It fell 3% on Nov 13, the session after its Nov 12 SEC filing (read the release).
−2Dilution
Down 3% on Nov 13, and still 14% under its Nov 12 close.
−2Dilution
IMMX's Quality Score rose 1 point on Fri, Nov 20, to -6. Gabriel S. Morris (CFO, President) bought $10K on Nov 18, filed Nov 20, and 1 more filing.
Follow IMMX's news. Pro members can get an alert when Immix Biopharma files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 132.1% more shares than a year ago |
| Latest filing | 8-K, Nov 12 |
Sat Dec 12: American Society of Hematology…Industry event · date confirmed.
After its last report it closed -2.9%.
The company says its cash lasts into mid-2028 (8-K, Nov 12).
CEO Ilya M. Rachman bought 1,408 shares on Nov 18. 1 more insider trade this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
IMMX is #206 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 206 |
Expected to report Fri Mar 12, after the close (in 111 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | +2.2% | -2.9% | -12.8% |
RSI 35.5, MACD below signal, below both averages. Not scored.
2 insiders bought $20K across 2 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: IMMX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
IMMX scores -6 today, which Breakaway calls Poor. It is #206 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 3% on Nov 13, and still 14% under its Nov 12 close. Shares: 2.3 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
IMMX scores -6 today, which Breakaway calls Poor (below zero). That is #206 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IMMX's -6.
2 insiders bought $20K across 2 filings in the last 6 months. No open-market sales on record. The newest is Gabriel S. Morris, CFO, President, who bought $10K on Nov 18. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.